Tag archive for ‘Copaxone patent’
Shiri Habib-Valdhorn On Tuesday, January 27th, 2015

Teva rivals urge US court to expedite Copaxone suit

Copaxone’s patent remains in force at least until the Federal Circuit Appeals Court reconsiders the case. The rivals of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) who are developing a More...

Nadav Neuman On Wednesday, January 21st, 2015

US Supreme Court upholds Copaxone patent

The ruling means Teva’s flagship multiple sclerosis treatment’s patent remains valid until September 2015.   The US Supreme Court has ruled in favor of Teva Pharmaceutical Industries Ltd. (NYSE: More...

Shiri Habib-Valdhorn On Sunday, November 30th, 2014

FDA again delays decision on Copaxone patent

– The decision gives Teva more time to transfer patients to its better patent protected double dosage Copaxone. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has filed a petition More...

Ilan Shavit On Wednesday, May 28th, 2014

European Patent Office upholds Copaxone patent

– The European Patent Office ruled in favor of Teva in a patent opposition proceeding filed by Synthon and Mylan. –   Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced More...

Globes On Monday, November 25th, 2013

Teva and Mylan Settle Copaxone Patent Litigation in France, the UK and the Netherlands

– The companies have agreed to settle pending patent litigation involving Copaxone in the UK, Netherlands and France. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) More...

Wordpress site Developed by Fixing WordPress Problems